Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27316517 | 0.98 | SOS2 (0.51) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| SCHEMBL1240176 | 0.83 | KMT2A (0.47) | — | |
| Ortetamine SCHEMBL27660676 | 0.83 | TAAR1 (0.52) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| Ortetamine SCHEMBL29388899 | 0.83 | TAAR1 (0.52) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| Ortetamine SCHEMBL209899 | 0.83 | TAAR1 (0.52) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| Ortetamine SCHEMBL42180 | 0.83 | TAAR1 (0.52) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| Ortetamine SCHEMBL3460028 | 0.83 | TAAR1 (0.52) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| SCHEMBL11677650 | 0.83 | GABRA1 (0.56) | SOS2MAOATAAR1SCN4AMAOB | |
| SCHEMBL19469882 | 0.82 | ESR1 (0.51) | SOS2MAOASLC6A2TAAR1SLC6A4 | |
| SCHEMBL19469880 | 0.82 | ESR1 (0.51) | SOS2MAOASLC6A2TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| CN-102170874-A | Compositions and methods for treating psychiatric disorders | GOSFORTH CT HOLDINGS PTY LTD | 2011-08-31 | — | — | CN | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| CN-1250519-C | Amine derivative with K channel regulation function and its preparing process and application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2006-04-12 | — | — | CN | claimed |
| CN-1250518-C | Amine derivative for preventing ischemic and anoxia damage of nerve and its medical application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2006-04-12 | — | — | CN | claimed |
| CN-1205175-C | Amine derivative possessing the function of anti-pulmonary hypertension and its application in pharmacological science | INST OF TOXICANT AND MEDICAMEN (CN) | 2005-06-08 | — | — | CN | claimed |
| CN-1415596-A | Amine derivative possessing the function of anti-pulmonary hypertension and its application in pharmacological science | INST OF TOXICANT AND MEDICAMEN (CN) | 2003-05-07 | — | — | CN | claimed |
| CN-1365967-A | Amine derivative with K channel regulation function and its preparing process and application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2002-08-28 | — | — | CN | claimed |
| CN-1365966-A | Amine derivative for preventing ischemic and anoxia damage of nerve and its medical application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2002-08-28 | — | — | CN | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4652458-A1 | SYSTEMS AND METHODS FOR MULTIPLEX DETECTION OF BIOMARKERS | Veravas, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250314642-A1 | METHODS FOR DEPLETION AND ENRICHMENT | VERAVAS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-12259385-B2 | Sample analysing device | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2025-03-25 | — | — | US | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| WO-2024155854-A1 | SYSTEMS AND METHODS FOR MULTIPLEX DETECTION OF BIOMARKERS | VERAVAS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024107708-A1 | TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION | ReJoy (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| EP-4304576-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023081753-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230105795-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | JAVED MOHAMMAD (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230091170-A1 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | VERAVAS, INC. | 2023-03-23 | — | — | US | disclosed |
| CN-115836224-A | Enrichment of antigen-specific antibodies for analytical and therapeutic uses | 维拉维斯公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4133271-A1 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | Veravas, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4096508-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | Javed, Mohammad (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022223613-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223612-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4079310-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079311-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| US-20220260557-A1 | METHODS FOR DEPLETION AND ENRICHMENT | VERAVAS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220137034-A1 | DETECTION AND QUANTIFICATION OF SMALL MOLECULES | MEDICQUANT APS (DK) | 2022-05-05 | — | — | US | disclosed |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3931566-A1 | DETECTION AND QUANTIFICATION OF SMALL MOLECULES | Aarhus Universitet (DK) | 2022-01-05 | — | — | EP | disclosed |
| CN-113777195-A | Analysis method of amphetamine drugs in environmental water sample, and special graphene-based three-dimensional macroscopic body material and solid-phase extraction device thereof | 公安部物证鉴定中心 | 2021-12-10 | — | — | CN | disclosed |
| US-20210302416-A1 | METHOD FOR DETECTING BIOMARKERS | VERAVAS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021154631-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | JAVED MOHAMMAD (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210199646-A1 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | VERAVAS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210190768-A1 | METHODS FOR DEPLETION AND ENRICHMENT | VERAVAS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3829734-A1 | METHODS FOR DEPLETION AND ENRICHMENT | Veravas, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3829759-A1 | METHOD FOR DETECTING BIOMARKERS | Veravas, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112823048-A | Elimination and enrichment method | 维拉维斯公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112823054-A | Method for detecting biomarkers | 维拉维斯公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10948484-B2 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-10 | — | — | US | disclosed |
| WO-2020023899-A1 | METHODS FOR DEPLETION AND ENRICHMENT | VERAVAS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023901-A1 | METHOD FOR DETECTING BIOMARKERS | VERAVAS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190328783-A1 | A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| EP-3172566-B1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LTD (GB) | 2019-10-16 | — | — | EP | disclosed |
| US-20190137484-A9 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10254203-B2 | Separation of proteins | MAGTIVIO B.V. (NL) | 2019-04-09 | — | — | US | disclosed |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford Burnham Prebys Medical Discovery Institute | 2019-01-24 | — | — | US | disclosed |
| EP-3429634-A1 | A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION | Cellectis (FR) | 2019-01-23 | — | — | EP | disclosed |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180311499-A1 | Treatment of Dermatological Conditions via Neuromodulation | PALO ALTO INVESTORS | 2018-11-01 | — | — | US | disclosed |
| US-20180292394-A1 | Sample depletion and enrichment to improve the quality of diagnostic test results | SOLDO JOSHUA CAINE (US) | 2018-10-11 | — | — | US | disclosed |
| CN-106706695-B | Utilize the detection method of miniature nuclear magnetic resonance chemical analyser qualitative analysis case drugs | 广西大学 | 2018-07-31 | — | — | CN | disclosed |
| US-10028971-B2 | Compositions and methods for treating psychiatric disorders | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2018-07-24 | — | — | US | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170307605-A1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2017184584-A1 | STABLE PACKAGING SYSTEM FOR MOISTURE AND OXYGEN SENSITIVE PHARMACEUTICAL DOSAGE FORMS | ASCENT PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017178586-A1 | A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION | CELLECTIS (FR) | 2017-10-19 | — | — | WO | disclosed |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | Sanford Burnham Prebys Medical Discovery Institute | 2017-08-24 | — | — | US | disclosed |
| EP-3172566-A1 | SAMPLE ANALYSING DEVICE | Intelligent Fingerprinting Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| CN-106706695-A | Detection method of qualitative analysis of case drugs by utilizing micro-nuclear magnetic resonance spectrometer | 广西大学 | 2017-05-24 | — | — | CN | disclosed |
| US-9649297-B2 | Treatment of ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2017-05-16 | — | — | US | disclosed |
| EP-3160961-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9396921-B2 | Method and apparatus for pyrolysis-induced cleavage in peptides and proteins | WYOMING RESEARCH PRODUCTS CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2016111731-A1 | ABUSE-DETERRENT OPIOIDS | BANNER LIFE SCIENCES LLC (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016012812-A1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | disclosed |
| WO-2015200534-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015195989-A1 | ENTERIC SOFT CAPSULE COMPOSITIONS | BANNER LIFE SCIENCES LLC (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150313877-A1 | TREATMENT OF ADHD | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-2938608-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015157150-A1 | OPIOID ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | BANNER LIFE SCIENCES LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157138-A1 | ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | BANNER LIFE SCIENCES LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9103804-B2 | Trace analyte extraction using adsorptive carbide-derived nanoporous carbon powders | BAE SYSTEMS INFORMATION AND ELECTRONIC SYSTEMS INTEGRATION INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2895246-A2 | SEPARATION OF PROTEINS | MagnaMedics GmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-20150185124-A1 | SEPARATION OF PROTEINS | MAGTIVIO B.V. (NL) | 2015-07-02 | — | — | US | disclosed |
| CN-104684548-A | Abuse deterrent pharmaceutical compositions for controlled release | EGALET LTD | 2015-06-03 | — | — | CN | disclosed |
| EP-2069790-B1 | BINDING SURFACES FOR AFFINITY ASSAYS | BECKMAN COULTER INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8957099-B2 | Treatment of ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2015-02-17 | — | — | US | disclosed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140284466-A1 | Method and Apparatus for Pyrolysis-induced Cleavage in Peptides and Proteins | THE UNIVERSITY OF WYOMING (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014106665-A1 | LABEL-FREE METHOD FOR THE DETECTION OF ANALYTES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-07-10 | — | — | WO | disclosed |
| EP-2752664-A1 | Label-free method for the detection of analytes | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | disclosed |
| CN-101529251-B | Binding surfaces for affinity assays | BECKMAN COULTER INC | 2014-04-02 | — | — | CN | disclosed |
| WO-2014040754-A2 | SEPARATION OF PROTEINS | MAGNAMEDICS GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
| US-8637325-B2 | Method and apparatus for pyrolysis-induced cleavage in peptides and proteins | UNIVERSITY OF WYOMING (US) | 2014-01-28 | — | — | US | disclosed |
| US-8518714-B2 | Binding surfaces for affinity assays | BECKMAN COULTER, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2129369-B1 | TREATMENT OF ADHD | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2013-06-05 | — | — | EP | disclosed |
| US-8455264-B2 | Fluorescence based detection of substances | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2013-06-04 | — | — | US | disclosed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | disclosed |
| EP-2505197-A1 | Treatment of ADHD | Gosforth Centre (Holdings) Pty Ltd (AU) | 2012-10-03 | — | — | EP | disclosed |
| EP-1915156-B1 | USE OF PSYCHOMOTOR STIMULANTS AND COMPOSITIONS CONTAINING THEM IN A METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | PROVIMI HOLDING B V (NL) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077284-A1 | Binding Surfaces for Affinity Assays | BECKMAN COULTER, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011116432-A1 | METHODS AND COMPOSITIONS FOR DETECTING BANNED SUBSTANCES | BOND UNIVERSITY LTD (AU) | 2011-09-29 | — | — | WO | disclosed |
| CN-102170874-A | Compositions and methods for treating psychiatric disorders | GOSFORTH CT HOLDINGS PTY LTD | 2011-08-31 | — | — | CN | disclosed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | disclosed |
| EP-2005179-B1 | FLUORESCENCE BASED DETECTION OF SUBSTANCES | UNIV EAST ANGLIA (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20110142957-A1 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | CARGILL THE NETHERLANDS HOLDING B.V. (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | disclosed |
| US-20110084203-A1 | METHOD AND APPARATUS FOR PYROLYSIS-INDUCED CLEAVAGE IN PEPTIDES AND PROTEINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-14 | — | — | US | disclosed |
| US-7893070-B2 | Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion | PROVIMI HOLDING B.V. (NL) | 2011-02-22 | — | — | US | disclosed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100087422-A1 | TREATMENT OF ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20100044560-A1 | Method and Apparatus for Pyrolysis-Induced Cleavage in Peptides and Proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | disclosed |
| EP-2129369-A1 | TREATMENT OF ADHD | Gosforth Centre (Holdings) Pty Ltd (AU) | 2009-12-09 | — | — | EP | disclosed |
| US-20090258860-A1 | XANTHINE DERIVATIVES FOR THE TREATMENT OF VASCULAR DEPRESSION | DUKE UNIVERSITY (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090230322-A1 | FLUORESCENCE BASED DETECTION OF SUBSTANCES | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2009-09-17 | — | — | US | disclosed |
| CN-101529251-A | Binding surfaces for affinity assays | BECKMAN COULTER INC (US) | 2009-09-09 | — | — | CN | disclosed |
| US-20090220617-A1 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | PROVIMI HOLDING B.V. | 2009-09-03 | — | — | US | disclosed |
| EP-2069790-A2 | BINDING SURFACES FOR AFFINITY ASSAYS | Beckman Coulter, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2005179-A2 | FLUORESCENCE BASED DETECTION OF SUBSTANCES | University of East Anglia (GB) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080199972-A1 | Spectroscopic Method For the Detection of Analytes | THERAINVENTION GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008095253-A1 | TREATMENT OF ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2008-08-14 | — | — | WO | disclosed |
| US-20080176340-A1 | Binding surfaces for affinity assays | BECKMAN COULTER, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| CN-101228441-A | Spectroscopic method for the detection of analytes | THERAINV GMBH (DE) | 2008-07-23 | — | — | CN | disclosed |
| WO-2008073146-A2 | METHOD AND APPARATUS FOR PYROLYSIS-INDUCED CLEAVAGE IN PEPTIDES AND PROTEINS | UNIVERSITY OF WYOMING (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008057366-A2 | BINDING SURFACES FOR AFFINITY ASSAYS | BECKMAN COULTER, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1915156-A2 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTIRINE EXHAUSTION | Provimi Holding B.V. (NL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008033754-A2 | XANTHINE DERIVATIVES IN METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION | DUKE UNIVERSITY (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064709-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION | DUKE UNIVERSITY (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1877797-A2 | EU/TB-CHELATE-BASED FLUORESCENCE SPECTROSCOPIC METHOD FOR DETECTING ANALYTES | Therainvention Gmbh (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007128133-A1 | HAIR SEQUESTERED TRACER FOR PROSTHESIS LEAK DETECTION | HADDON DAVID JAMES (CA) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007110605-A2 | FLUORESCENCE BASED DETECTION OF SUBSTANCES | UNIVERSITY OF EAST ANGLIA (GB) | 2007-10-04 | — | — | WO | disclosed |
| US-20070141710-A1 | Stable calibrators for immunoassays | BECKMAN COULTER, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007021189-A2 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTIRINE EXHAUSTION | PROVIMI HOLDING B.V. (NL) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006116981-A2 | EU/TB-CHELATE-BASED FLUORESCENCE SPECTROSCOPIC METHOD FOR DETECTING ANALYTES | THERAINVENTION GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| CN-1250519-C | Amine derivative with K channel regulation function and its preparing process and application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2006-04-12 | — | — | CN | disclosed |
| CN-1250518-C | Amine derivative for preventing ischemic and anoxia damage of nerve and its medical application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2006-04-12 | — | — | CN | disclosed |
| CN-1205175-C | Amine derivative possessing the function of anti-pulmonary hypertension and its application in pharmacological science | INST OF TOXICANT AND MEDICAMEN (CN) | 2005-06-08 | — | — | CN | disclosed |
| CN-1415596-A | Amine derivative possessing the function of anti-pulmonary hypertension and its application in pharmacological science | INST OF TOXICANT AND MEDICAMEN (CN) | 2003-05-07 | — | — | CN | disclosed |
| CN-1365967-A | Amine derivative with K channel regulation function and its preparing process and application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2002-08-28 | — | — | CN | disclosed |
| CN-1365966-A | Amine derivative for preventing ischemic and anoxia damage of nerve and its medical application | INST OF TOXIC MEDICAL MATERIAL (CN) | 2002-08-28 | — | — | CN | disclosed |
| CN-1037330-A | PROPANAMINE DERIVATIVES | LILLY CO ELI (US) | 1989-11-22 | — | — | CN | disclosed |
| CN-1037330-A | PROPANAMINE DERIVATIVES | LILLY CO ELI (US) | 1989-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | SLC6A3, SLC6A2, SLC18A2 | SOS2 1138/4885MAOA 481/4885SLC6A2 2/4885 |
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20110084203-A1 | METHOD AND APPARATUS FOR PYROLYSIS-INDUCED CLEAVAGE IN PEPTIDES AND PROTEINS | DNPEP, PGA5, PEPD | SOS2 4427/4885MAOA 3279/4885SLC6A2 4767/4885 |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | SOS2 3264/4885MAOA 47/4885SLC6A2 134/4885 |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20170240514-A1 | Small Molecule Agonists of Neurotensin Receptor 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20090258860-A1 | XANTHINE DERIVATIVES FOR THE TREATMENT OF VASCULAR DEPRESSION | TPH1, HTR5A, XDH | SOS2 2327/4885MAOA 13/4885SLC6A2 4/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | SOS2 3318/4885MAOA 139/4885SLC6A2 98/4885 |
| US-20080064709-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION | TPH1, HTR5A, SLC6A2 | SOS2 2532/4885MAOA 19/4885SLC6A2 3/4885 |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | SOS2 2389/4885MAOA 1473/4885SLC6A2 322/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | SOS2 679/4885MAOA 667/4885SLC6A2 140/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | SOS2 3915/4885MAOA 64/4885SLC6A2 138/4885 |
| US-20080199972-A1 | Spectroscopic Method For the Detection of Analytes | IL6, TNF, TIA1 | SOS2 4308/4885MAOA 952/4885SLC6A2 1282/4885 |
| US-20100044560-A1 | Method and Apparatus for Pyrolysis-Induced Cleavage in Peptides and Proteins | DNPEP, PGA5, PEPD | SOS2 4427/4885MAOA 3279/4885SLC6A2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.